| Literature DB >> 29997579 |
Xiaoqing Hu1,2,3,4, Ying-Ying Huang3,4, Yuguang Wang3,4,5, Xiaoyuan Wang1, Michael R Hamblin3,4,6.
Abstract
Biofilm describes a microbially-derived sessile community in which microbial cells are firmly attached to the substratum and embedded in extracellular polymeric matrix. Microbial biofilms account for up to 80% of all bacterial and fungal infections in humans. Biofilm-associated pathogens are particularly resistant to antibiotic treatment, and thus novel antibiofilm approaches needed to be developed. Antimicrobial Photodynamic therapy (aPDT) had been recently proposed to combat clinically relevant biofilms such as dental biofilms, ventilator associated pneumonia, chronic wound infections, oral candidiasis, and chronic rhinosinusitis. aPDT uses non-toxic dyes called photosensitizers (PS), which can be excited by harmless visible light to produce reactive oxygen species (ROS). aPDT is a multi-stage process including topical PS administration, light irradiation, and interaction of the excited state with ambient oxygen. Numerous in vitro and in vivo aPDT studies have demonstrated biofilm-eradication or substantial reduction. ROS are produced upon photo-activation and attack adjacent targets, including proteins, lipids, and nucleic acids present within the biofilm matrix, on the cell surface and inside the microbial cells. Damage to non-specific targets leads to the destruction of both planktonic cells and biofilms. The review aims to summarize the progress of aPDT in destroying biofilms and the mechanisms mediated by ROS. Finally, a brief section provides suggestions for future research.Entities:
Keywords: biofilm-related infections; microbial biofilms; photochemical mechanisms; photodynamic therapy; photosensitizer structure; reactive oxygen species
Year: 2018 PMID: 29997579 PMCID: PMC6030385 DOI: 10.3389/fmicb.2018.01299
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Jablonski diagram for ROS generation by aPDT via type I and type II photodynamic mechanisms. Both types of ROS can damage biomolecules and destroy or kill all known classes of pathogenic microorganisms.
PS chemical structures employed in aPDI and antibiofilm studies.
| SAPYR | Synthesized by Cieplik et al. according to patent No. WO/2012/113860 | Cieplik et al., | |
| Photogem | Tim Tec Corp., Newark, USA | Silva et al., | |
| PyP | Synthesized by Prasanth et al. | Prasanth et al., | |
| RLP068/Cl | Molteni Therapeutics, Florence, Italy | Vassena et al., | |
| Cationic BODIPY | Prepared in ref. (Caruso et al., | Orlandi et al., | |
| Tetra-Py+-Me | Prepared in refs (Carvalho et al., | Beirão et al., | |
| ClAlPc | Sigma-Aldrich Co. (St. Louis, MO) | Ribeiro et al., | |
| FSc | Synthesized in the Department of Chemistry of University of Minho (Frade et al., | Lopes D. et al., | |
| TBO | Sigma-Aldrich Co. (St. Louis, MO) | Tennert et al., | |
| MB | Sigma-Aldrich Co. (St. Louis, MO) | Garcez et al., | |
| Erythrosine | Sigma-Aldrich Co. (St. Louis, MO) | Cho et al., | |
| Curcumin | Sigma-Aldrich Co. (St. Louis, MO) | Manoil et al., | |
| XF-73 | Synthesized by Destiny Pharma, Brighton, UK | Gonzales et al., |
Figure 2Composition of bacterial biofilms and possible aPDT targets. DNA, lipids (Alves et al., 2013a,b; Lopes D. et al., 2014), proteins (Konopka and Goslinski, 2007; Gracanin et al., 2009; Dosselli et al., 2012), DNA (Rabea et al., 2003; Lam et al., 2011), and polysaccharides (Beirão et al., 2014) can all be damaged by aPDT-generated ROS.
Figure 3Cell wall structures of G− bacteria, G+ bacteria and fungus and possible aPDT targets. The plasma membrane (Alves et al., 2013a,b; Melo et al., 2013; Lopes D. et al., 2014) and transmembrane proteins (Konopka and Goslinski, 2007). can be destroyed by aPDT-generated ROS.
Anti-biofilm aPDT studies in preclinical infections in animal models.
| Bioluminescent | 6-week-old male BALB/c mice | Chlorin e(6) [Ce(6)] (10 mg/kg mice) | 664 nm, 100 J/cm2 | Marked reduction (immediately); and complete reduction (5 d) | 24 h | Park et al., |
| MRSA ATCC 6538 and 7 clinical isolates | Female Wistar rats (200 ± 10 g, | HY-NPs (0.124 μM) | 23.5 J/cm2 | Disappearance (10 d after aPDT) | 1 day | Nafee et al., |
| MRSA ATCC 33591 | 8 to 10-week-old male C57BL/ksj db/db mice (Japan) | 5-ALA (200 mg/kg) | 410 nm, 164.5 mW/cm2, 50 J/cm2 | Decrease | 2 days | Morimoto et al., |
| Male BALB/c mice (20–30 g) | PTMPP [500 μM (100 μl)] | 635 ± 15 nm, 84 mW/cm2, 211 J/cm2, 42 min | Above 98% | 24 h | Lambrechts et al., | |
| MRSA Xen31 | Female BALB/c mice (6–8 weeks, 17–21 g) | Conjugate PEI–ce6 (ε400 nm = 150,000/Mcm) | 660 ± 15 nm, 100 mW/cm2, 360 J/cm2 | 2.7 log10 | 30 min | Dai et al., |
| Adult female BALB/c mice (6–8 weeks; 17–21 g) | PEI-ce6 conjugate [800 to 900 μM (50 μl)] | 660 nm, 100 mW/cm2, 240 J/cm2 | Over 3 log10 (30 min); 1.7 log10 (1 day and 2 days) | 30 min, 1 day, 2days | Dai et al., | |
| Female Swiss mice (6 weeks) | Photogem [1000 mg/l (30 μl)] | 455 nm, 305 J/cm2, 20 min | 1.41 log10 | 4 days | Mima et al., | |
| Female Swiss mice (6 weeks) | Photogem [500 mg/l (30 μl)] | 630 nm, 305 J/cm2, 20 min | 1.59 log10 | 4 days | Mima et al., | |
| Adult male mice (30–60 g) | ER [400 μmol/l (50 μl)] | 532 ± 10 nm, 90 mW, 14.34 J/cm2, 3 min | 0.73 log10 | 24 h | Costa et al., | |
| A clinical patient | Experimental beige nude mice with severe combined immunodeficiency disease | MB [500 μg/ml (0.05 ml)] | 664 nm, 400 mW, 275 J/cm2, 687.5 s | 2.74 log10 from oral cavity | 4 weeks | Teichert et al., |
| BALB/c female mice (7–8 weeks) | MB (1 mmol/l) | 660 nm, 1.67 mW/cm2, 15 J/cm2, 2.5 h | Total prevention | 72 h | Cernáková et al., | |
| Bioluminescent | Rats ( | ALA (300 mg/kg) | 635 ± 10 nm, 4.3 mW/cm2, 75 J/cm2, 4 h | Effective against biofilms in bone | 16–21 days | Bisland and Burch, |
| Bioluminescent | Female Sprague-Dawley CD rats (250–300 g) | ALA (300 mg/kg) | 635 ± 10 nm, 4.3 mW/cm2, 75 J/cm2, 4 h | Inhibition of biofilm implants in bone | 10 days | Bisland et al., |
| Adult female BALB/c mice (7–8 weeks; 17–21 g) | New methylene blue [400 μM (50 μl)] | 660 ± 15 nm, 120 J/cm2 | Significant reduction | 24 h | Dai et al., | |
| C57BL/6 mice | TB (0.2% in the gel) | 630 nm, 42 J/cm2, 10 min | 87% | 7 days | Baltazar et al., | |
| Male BALB/c mice (6–8 weeks, 20–25 g) | BPD (0.5 mg/kg) | 690 nm, 65 mW/cm2, 60 J/cm2, 920 s | 0.7 log10 | N/A | O'Riordan et al., | |
| Male BALB/c mice (6–8 weeks) | EtNBSe (5.25 mg/kg) | 635 nm, 60-65 mW/cm2, 60 J/cm2, 920 s | Above 2 log10 | N/A | O'Riordan et al., | |
| MRSA ATCC 33592 | EpiDerm FT™ Full Thickness Skin Model | MB (0.01%) | 670 nm, 96 J/cm2, 120 s | 5.1 log10 (immediately) and 5.9 log10 (24 h after aPDT) | 24, 48, 72 h | Street et al., |
| 30 Mongolian Gerbils | Photogem [1 mg/ml (20 μl)] | 632 nm, 100 mW, 90 J, 15 min | killing | 2 days | Jung et al., | |
ALA, aminolevulinic acid; BPD, benzoporphyrin derivative; ER, erythrosine; EtNBSe, 5-ethylamino-9-diethylaminobenzo[a]phenoselenazinium chloride; HY-NPs, hypericin-laden nanoparticles; MB, methylene blue; PEI, polyethylenimine; Photogem: chemical structure shown in Table .
Anti-biofilm aPDT studies in human clinical trials.
| 62 patients aged C18 years | RLP068/Cl (0.50% in the gel) | 689 ± 5 nm, 60 J/cm2, 500 s | 3.00 ± 1.82 log10 | Mannucci et al., | |
| MSSA and MRSA, | 32 patients with chronic ulcers (16 venous leg ulcers, 16 diabetic foot ulcers) | PPA904 (500 μM) | 570–670 nm, 50 J/cm2 | 2.5 log10 (immediately) | Morley et al., |
| 8 periodontal pathogens including | six patients diagnosed with chronic periodontitis (CP) | Ce6 (C34H36N4O6, 100 mg/ml in 0.9% NaCl solution) | The continuous water-filtered spectrum covers 570–1400 nm (broad-band visCwIRA radiator), with local minima at 970, 1200, and 1430 nm, due to the absorption of water molecules. 200 mW/ cm2, 300 s | About 3.6 log10 for aerobic bacteria and 4 log10 for anaerobic bacteria | Al-Ahmad et al., |
| 24 patients with localized chronic periodontitis (32–58 year old) | Phenothiazine chloride (N/A) | 660 nm, 60 mW/cm2 | Significant reduction of DNA concentration after 12 weeks | ||
| 13 HP positive volunteers | ALA (20 mg/kg) | 410 nm, 50 J/cm2 | Greatly reduced | Wilder-Smith et al., | |
| 10 patients (21-80 year old) | None | 405 nm, 200 mW/cm2, 40 J/cm2 | 91% | Ganz et al., | |
| 18 adults with | None | 408 nm, 15 min (5 patients), 30 min (5 patient), 45 min (7 patients), 60 min (1 patient) | Above 97% (in the antrum), above 95% (body), and above 86% (fundus) | (Lembo et al., | |
Ce6, Chlorine e6; PPA904, 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide; RLP068/Cl, {1(4),8(11),15(18),22(25)-tetrakis[3-(N,N,Ntrimethylamonium)phenoxy]phthalocyaninato} zinc(II) chloride.